• Upcoming Meetings and Conferences
• Past Meetings
  • Cross-Cutting Issues
  • Biological Threats
  • Chemical Threats
  • Radiological/Nuclear Threats
• Videocast Library and Online Training
• Committee Meetings

Public Workshop: Blood Establishment Computer Software
July 10-11, 2008

HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop 2008
September 24 – September 26, 2008

Cross-Cutting Issues

Inaugural Meeting of National Biodefense Science Board (NBSB)
December 17-18, 2007

Anthrax Vaccines: Bridging Correlates Of Protection In Animals To Immunogenicity In Humans November 8, 2007 transcript. - November 9, 2007 transcript.
Novermber 8, 2008

HHS Assistance Secretary of Preparedness and Response (ASPR) Pandemic and All-Hazards Preparedness Act (PAHPA) Implementation Discussion
November 8, 2007

2007 Biomedical Advanced Research and Development Authority (BARDA) Industry Day
August 3, 2007

HHS PHEMC Enterprise Stakeholders Workshop
July 31 – August 2, 2007

BioShield Stakeholders Workshop
September 24-25, 2006

Eleventh Annual Conference on Vaccine Research
May 5-7, 2008

Accelerating the Development and Availability of Vaccines for a Pandemic or other Emerging Threats: Present and Future
pril 20, 2006

Workshop on the Development of Broad Spectrum Therapeutics
April 18, 2006

NIAID Monoclonal Antibody Therapeutics for Biodefense and Emerging Infectious Diseases Workshop
March 29, 2006

How fast can a new vaccine for an emerging respiratory virus be developed and available for use?
March 22, 2006

NIAID Expert Panel on Botulinum Neurotoxins Therapeutics
February 9-10, 2004

Aerosol Challenge Technology and Applications in Biodefense
December 3-4, 2003

NIAID Expert Panel on Botulinum Diagnostics
March 23, 2003

NIAID Expert Panel on Botulinum Toxins
November 20, 2002

NIAID Expert Panel on Immunity and Biodefense
June 17, 2002

Chemical Threats

NINDS Counterterrorism and Neuroscience Workshop
April 7-8, 2004

NIAID Expert Panel Workshop on Ricin
April 1-2, 2004

NIAID Expert Panel Review on Medical Chemical Defense
March 19, 2003

Radiological/Nuclear Threats

Radiation Epidemiology Course - Radiation Epidemiology Branch (REB), Division of Cancer Epidemiology & Genetics (DCEG), National Cancer Institute (NCI), National Institutes of Health (NIH)
May 14-17, 2007

Center for Medical Countermeasure against Radiation (CMCR), 2006 Annual Meeting Report
June 7-8, 2006

Centers for Medical Countermeasures against Radiation (CMCR) 2005 Meeting Report
November 7-8, 2005

Animal Models of Radiation Injury, Protection, and Therapy
May 25-26, 2004

Hematopoietic Stem Cell Expansion and Immune Reconstitution
May 17, 2004

Models and Procedures for Evaluating Radioprotectors
December 3-4, 2003

Models for Evaluating Agents Intended for the Prophylaxis, Mitigation and Treatment of Radiation Injuries: Report of an NCI Workshop
December 3–4, 2003

Molecular and Cellular Biology of Moderate-Dose (1–10 Gy) Radiation and Potential Mechanisms of Radiation Protection: Report of a Workshop
December 17–18, 2001

Modifying Normal Tissue Damage Postirradiation: Report of a Workshop Sponsored by the Radiation Research Program, National Cancer Institute
September 6–8, 2000

NIH Videocasting: Online library which contains videocasts on a variety of topics, including issues in emergency preparedness and biodefense.

CDC Emergency Preparedness and Response Training Resources: Online resource training materials, which includes information on topics ranging from basic introductory materials to information on laboratory training and risk communication.

National Science Advisory Board for BioSecurity (NSABB): The NSABB has been established to provide advice to federal departments and agencies on ways to minimize the possibility that knowledge and technologies emanating from vitally important biological research will be misused to threaten public health or national security. The NSABB is a critical component of a set of federal initiatives to promote biosecurity in life science research.

Vaccines and Related Biological Products Advisory Committee: The Committee reviews and evaluates data concerning the safety, effectiveness, and appropriate use of vaccines and related biological products which are intended for use in the prevention, treatment, or diagnosis of human diseases, and, as required, any other product for which the Food and Drug Administration has regulatory responsibility. The Committee also considers the quality and relevance of FDA's research program which provides scientific support for the regulation of these products and makes appropriate recommendations to the Commissioner of Food and Drugs.